Podcasts about initial management

AUA2025: Embracing Multi-Disciplinary Care for Advanced Prostate Cancer: A Case-Based Update 2025 CME Available: https://auau.auanet.org/node/42997 At the conclusion of this activity, participants will be able to: 1. Initial Management of Metastatic Prostate Cancer: Evaluate and treat a patient with new diagnosed M1 prostate cancer with androgen deprivation therapy (ADT) plus be skilled to offer novel oral antiandrogens. Furthermore, to recognize high-volume new M1 prostate cancer so as to be able to partner with GU medical oncologist for docetaxel chemotherapy in a multidisciplinary team. 2. Non-Metastatic Castrate Resistant Prostate Cancer (M0 CRPC): The learner will be skilled to diagnose M0 CRPC and be able to educate patients about using either enzalutamide or apalutamide or darolutamide added to traditional ADT as a way to improve their patent's overall and radiographic progression-free survival. Furthermore, the skilled learner will be able to understand the differences between these three oral agents and to educate patients about side-effects and toxicities. Finally, understand the pros and cons of PSMA PET scan imaging in further staging in this disease Non-metastatic Castrate-Resistant Prostate Cancer (M0 CRPC): Diagnose M0 CRPC and be able to educate patients about using novel oral antiandrogens added to traditional ADT as a way to improve their patent's overall and radiographic progression-free survival. Furthermore, the skilled learner will be able to understand the differences between these novel oral agents and to educate patients about side effects and toxicities. Finally, understand the pros and cons of PSMA PET scan imaging in further staging in this disease state. 3. Metastatic Castrate-Resistant Prostate Cancer (M1 CRPC): Describe and have a working knowledge of the latest phase III RCT results for new therapies in M1 CRPC and be able to educate their patients on treatment options and participate in a multidisciplinary team caring for men with this disease state of far-advanced prostate cancer. 4. Describe that advanced prostate cancer is a complex group of disease states with an ever-changing therapeutic landscape and for providers and teams to embrace the multi-disciplinary nature of care for our patients. 5. Identify the molecular and molecular genetic underpinnings of advanced prostate cancer and recognize the future will be based on a more personalized therapy landscape including PARP inhibition, immune checkpoint agents, and novel AR targeted agents emerging in 2025 and beyond.

Featuring slide presentations and related discussion from Dr Hanny Al-Samkari, Dr James B Bussel and Prof Nichola Cooper, including the following topics: Introduction (0:00) Clinical Manifestations and Initial Management of Immune Thrombocytopenia (ITP) — Dr Al-Samkari (10:24) Second- and Later-Line Therapies for ITP — Dr Bussel (1:00:51) Tolerability and Other Practical Considerations with Available Treatment Strategies for Persistent/Chronic ITP — Prof Cooper (1:28:08) CME information and select publications

This week, we kick off a new, highly-anticipated and highly-requested series, covering venous thromboembolism (VTE). In this first episode, we discuss how we make the initial diagnosis and how we approach initial management. As a clinician, you will undoubtedly come across the need to make this decision. This episode and this series will set you up for success!Episode contents:-What is venous thromboembolism?- How do we diagnose patients with VTE?- How do we initially management patients with VTE? - How do we select anticoagulants for VTE? ****This episode is sponsored by our Global Research Partners! Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

AUA Guidelines: Diagnosis And Treatment Of Idiopathic Overactive Bladder Co-Host: Anne Pelletier Cameron, MD, FRCSC, URPS Segment #1: Is this an update to the prior Guideline? Segment #2: What is new in the Diagnosis, ntitial Assessment and Initial Management of OAB? Segment#3: What does the Guideline say about Oral Medication? Segment #4: What's new in minimally invasive prodcedures Segment #5: UDS and Cystoscopy Segment #6: What is new and exciting on the horizion for OAB Segment #7: Where to start and the most impactpact research in this area The AUA/SUFU Guideline on the Diagnosis and Treatment of Idiopathic Overactive Bladder Cameron AP, Chung DE, Dielubanza EJ, et al. The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder. J Urol. Published online April 23, 2024. doi:10.1097/JU.0000000000003985. https://www.auajournals.org/doi/10.1097/JU.0000000000003985

In this week's episode, we continue onto part two of our three-part discussion on AML induction, this week focusing on selecting our up-front regimen. Be sure to check out last week's episode, as this one builds on that one. Also, if you have not done so, please do check out our hemepath series to ensure you can more easily follow along with this conversation!Episode contents: - What is "7+3"? - How do we pick our approach to management?- Do we ever add anything else to our induction back bone? ****Have some time and want to make some extra money? Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

Join us as Sandhya Pruthi, MD talks us through basics of breast cancer, specifically how to share a new diagnosis with a patient, the spectrum of disease from favorable to more aggressive, and the basics of what to expect with initial treatment. Feel more confident sharing a new diagnosis of breast cancer and supporting your patients through this journey. Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments 00:00 Introduction 02:18 Getting to Know Dr Sandhya Pruthi 09:49 Picks of the Week 12:35 Case 1: Diagnosis and Treatment of ductal carcinoma in situ (DCIS) 21:24 Risk Stratification and Active Surveillance for DCIS 23:43 Genetic Testing Recommendations 28:08 Case 2: Evaluation and Diagnosis of a Breast Lump 39:14 Invasive Ductal Carcinoma 47:49 Initial Management of invasive ductal carcinoma (IDC) 48:19 Preoperative Discussion and MRI 49:19 Lumpectomy and Sentinel Lymph Node Biopsy 50:16 Radiation and Hormonal Adjuvant Therapy 51:46 Considerations for Chemotherapy 55:51 Signs of Late Recurrence or Metastasis 58:20 Screening Guidelines and Age 01:02:25 Importance of Breast Self-Awareness Credits Written and produced, Show Notes:  Molly Heublein MD Infographic and Cover Art: Edison Jyang Hosts: Molly Heublein MD, Era Kryzhanovskaya MD  Reviewer: Leah Witt, MD Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Sandhya Pruthi MD Sponsor: Freed You can try Freed for free right now by going to freed.ai Listeners of Curbsiders can use code CURB50 for $50 off their first month.  Sponsor: Babbel Get 50% off at Babbel.com/CURB Sponsor: NetSuite Get your own KPI Checklist at NetSuite.com/CURBSIDERS

Learn practical tips for the inpatient management of patients with sickle cell disease and vaso-occlusive crisis from guest, Dr. Yoo Mee Shin (Emory). We cover acute pain management including adjuvant therapies, IV fluids, oxygen therapy, the management of acute chest syndrome, and when to perform simple vs exchange transfusions. Key takeaways include the importance of early triage and analgesia, addressing misconceptions about opioid use disorder in patients with sickle cell disease, and recognizing complications of vaso-occlusive crises. Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments 00:00 Intro 01:27 Getting to know our guest 07:48 Case Presentation and Initial Management of Sickle Cell Disease (SCD) 13:46 Misconceptions about opioid use disorder and sickle cell 17:02 Management of Acute Pain in Sickle Cell Disease 25:46 Adjuvant therapy for pain 29:04 Transition to outpatient care 32:46 General admission orders for sickle cell 38:44 Management of Acute Chest Syndrome 42:01 Simple vs exchange transfusion 47:08 Transfusion in preoperative and pregnant patients 48:03 Transitions and follow-up care 49:35 Key takeaways and Outro Credits Written and Produced by:  Matthew Watto MD, FACP Cover Art & Infographic: Matthew Watto MD, FACP Hosts: Matthew Watto MD, FACP; Paul Williams MD, FACP    Reviewer: Emi Okamoto MD Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Yoo Mee Shin MD Sponsor: Green Chef Go to greenchef.com/60curb and use code 60curb to get 60% off, plus 20% off your next two months. Sponsor: NetSuite Download NetSuite's popular KPI Checklist, designed to give you consistently excellent performance -absolutely free, at NetSuite.com/CURBSIDERS

In this episode, we're joined by Dr. David Capehorn, Honorary Associate Specialist and Expert in Paediatrics, who's been at the forefront of the Primary-Secondary Care interface for 30 years. With reference to two classic cases, David helps us navigate key learning from the new 2022 NICE guidelines on correct management of UTIs in children and his own summary article on identifying and treating UTIs promptly for under 16s. More specifically, we discuss: Diagnosis Urine interpretation When to send urine for culture tests Immediate management Follow-up investigations Referral And prevention   Feedback: Let us know what you thought about this episode of BNSSG Paeds Pod here, via our feedback form! Completing the form should take between 1-3 minutes, and your responses are invaluable in helping Ruth and the team to shape future episodes.   Episode resources: “⁠Identify and Treat Urinary Tract Infection Promptly in Under 16s⁠” by Dr. David Capehorn⁠ NICE Urinary Tract Infections in Under 16s: Diagnosis and Management guidelines⁠⁠ BNSSG Remedy Urinary Tract Infection in Children: Management and Referral guidelines⁠⁠ NICE Fever in Under 5s: Assessment and Initial Management guidelines ⁠⁠ERIC – The Children's Bowel & Bladder Charity⁠

Buckle up, PGY-1's! Intern year is starting whether you're ready or not. Don't fret, BTK has your back to make sure you dominate the first year of residency.  Today, we're hitting the wards and tackling some of the scary clinical scenarios you will see as an intern. Hosts: Shanaz Hossain, Nina Clark Tips for new interns: THINGS TO REMEMBER ·       BREATHE. In most cases, you have a little bit of time – at least enough to take a breath and calm down outside the room before heading into an emergency. Panic doesn't help anybody. ·       See the patient. Getting a bunch of pages? Worried about someone? Confused as to what's going on? Go see the patient and chat with the bedside team. ·       Know your toolbox. There are a ton of people around who can help you in the hospital, and knowing the basic labs/imaging studies and when to use them can help you to triage even the sickest patients. ·       Load the boat. You've heard this one from us all week! Loop senior level residents in early. HYPOTENSION ·       Differential: measurement error, patient's baseline, and don't miss – SHOCK.            - Etiologies of shock: hemorrhagic, hypovolemic, ·       On the phone: full set of vitals, accurate I/Os, ·       On the way: recent notes, PMH/PSH including from this hospital stay, and vitals/I&Os/studies from earlier in the day ·       In the room: ABCDs – rapidly gives you a sense of how high acuity the patient is ·       Get more info: labs, consider imaging, work up specific types of shock based on clinical concern. ·       Initial management: depends on etiology of hypotension; don't forget to consider peripheral or central access, foley catheterization for close monitoring of urine output, and level of care  HYPOXEMIA ·       Differential: atelectasis, baseline pulmonary disease, pneumonia, PE, hemo/pneumothorax, volume overload ·       On the phone: full set of vitals, amount of supplemental oxygen required and delivery device, rate of escalation in oxygen requirement ·       On the way: review PMH/PSH, known injuries (known hemothorax/pneumothorax? Rib fractures? Chest tubes in already?), risk factors for DVT/PE, review I/Os for evidence of volume status, vitals and labs for evidence of infection ·       In the room: ABCDs, pulmonary and cardiac exam, volume status exam ·       Get more info: basic labs, ABG if worried about oxygenation, CXR, consider bedside US of the lungs/heart, if high suspicion for PE consider CTA chest ·       Initial Management: supplemental O2, higher level of care, consider intubation or other supplemental oxygenation adjuncts, additional management dependent on suspected etiology ·       ABG Vs VBG (IBCC): https://emcrit.org/ibcc/vbg/  ALTERED MENTAL STATUS ·       Differential: stroke, medication effect, hypoxemia or hypercarbia, toxic or medication effect, endocrine/metabolic, stroke or MI, psychiatric illness, or infections, delirium ·       On the way: review PMH/PSH, recent notes for evidence of altered mentation or agitation, or signs hinting at above etiologies ·       In the room: ABCDs, focal neuro deficits?, alert/oriented? Be sure the patient's mental status is adequate for airway protection! ·       Get more info: basic labs, blood gas/lactate, CT head noncontrast if concerned for stroke. ·       Initial management: rule out above; if concerned about delirium, optimize sleep/wake cycles, pain control, and lines/drains/tubes.  OLIGURIA ·       Differential: prerenal due to hypovolemia or low effective circulating volume, intrinsic renal disease, post-renal obstruction ·       On the phone: clarify functional foley or bladder scan results, full set of vitals ·       On the way: review PMH/PSH, known injuries (known hemothorax/pneumothorax? Rib fractures? Chest tubes in already?), risk factors for DVT/PE, review I/Os for evidence of volume status, vitals and labs for evidence of infection ·       In the room: ABCDs, confirm functioning foley catheter ·       Get more info: basic labs, urine electrolytes, consider fluid challenge to evaluate responsiveness, consider adjuncts including renal US ·       Initial management: typically consider IVF bolus initially, but if patient not volume responsive, don't overload them -- look for other etiologies!  TACHYCARDIA ·       Differential: sinus tachycardia (pain, hypovolemia, agitation, infection), cardiac arrhythmia, MI, PE ·       On the phone: full set of vitals, acuity of change in heart rate, updated I/Os ·       On the way: Review PMH/PSH, known cardiac history, cardiac and PE risk factors, volume resuscitation, signs concerning for infection, updated I/Os ·       In the room: ABCDs, cardiac/pulmonary exam, evaluate for any localizing signs for infection ·       Get more info: basic labs, EKG, consider CXR, troponins ·       Initial management: depends heavily on etiology Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more. If you liked this episode, check out our new how-to video series on suture and knot-tying skills – https://behindtheknife.org/video-playlists/btk-suture-practice-kit-knot-tying-simulator-how-to-videos/

Featuring perspectives from Ms Courtney Arn, Dr David M O'Malley, Dr Richard T Penson and Ms Jaclyn Shaver, including the following topics: Introduction (0:00) Overview of Ovarian Cancer (4:50) Initial Management of Advanced Ovarian Cancer (26:41) Up-Front PARP Inhibitor Maintenance Therapy (33:10) Side Effects and Toxicities of PARP Inhibitors (37:07) Antibody-Drug Conjugates (1:02:13) Future Directions — Tumor Treating Fields (1:20:12) NCPD information and select publications

Dr. Katherine Virgo discusses the latest evidence-based guideline recommendation updates regarding initial management of metastatic prostate cancer based on the new clinical trial results comparing triplet therapies (the addition of darolutamide, abiraterone, or enzalutamide to docetaxel plus androgen deprivation therapy) to standard of care. Dr. Virgo also discusses cost of treatment options and ongoing research questions in this field. Read the full guideline, “‘Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update” at www.asco.org/genitourinary-cancer-guidelines. TRANSCRIPT This guideline, clinical tools, and resources are available at www.asco.org/genitourinary-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest disclosures in the Journal of Clinical Oncology, https://ascopubs.org/doi/10.1200/JCO.23.00155.  Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts.   My name is Brittany Harvey, and today I am interviewing Dr. Katherine Virgo from Emory University, lead author on the ‘Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer: ASCO Guideline Update'.   Thank you for being here, Dr. Virgo.  Dr. Katherine Virgo: Thank you.  Brittany Harvey: Before we discuss this guideline, I'd just like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Virgo, are available online with the publication of the guideline update in the Journal of Clinical Oncology, which is linked in the show notes.    So then, getting into the content of this update first, Dr. Virgo, what prompted this update to the initial management of noncastrate advanced, recurrent or metastatic prostate cancer guideline?  Dr. Katherine Virgo: The update is primarily driven by new clinical trial results comparing triplet therapies to standard of care. Triplet therapy here refers to the addition of darolutamide, abiraterone, or enzalutamide to docetaxel plus androgen deprivation therapy for patients with de novo metastatic noncastrate prostate cancer.  Brittany Harvey: Great. And then, based on this, what are the new and updated recommendations from the guideline panel?   Dr. Katherine Virgo: The first updated recommendation adds darolutamide to the list of treatment options as follows: docetaxel, abiraterone, enzalutamide, apalutamide or darolutamide, each when administered with androgen deprivation therapy, represent five separate standards of care for noncastrate metastatic prostate cancer, with the exception of the triplet therapies of docetaxel plus abiraterone plus ADT and docetaxel plus darolutamide plus ADT. The use of any of these agents in any other particular combination or in any particular series cannot yet be recommended.   The second updated recommendation states: for patients with metastatic noncastrate prostate cancer with high volume disease as defined per CHAARTED, who are candidates for treatment with chemotherapy but are unwilling or unable to receive triplet therapy, for example, due to insurance constraints, docetaxel plus ADT should be offered. We add some practical information here. Patients should be made aware that doublet therapy, docetaxel plus ADT, has inferior overall survival compared to triplet therapy, such as abiraterone and prednisone plus docetaxel plus ADT.   Then, I have a few recommendations here with respect to triplet therapy, and these are new. For patients with de novo metastatic noncastrate prostate cancer with high volume disease as defined per CHAARTED who are being offered ADT plus docetaxel chemotherapy, triplet therapy, abiraterone and prednisone plus ADT and docetaxel should be offered per the PEACE-1 trial. Abiraterone and prednisone plus ADT and docetaxel demonstrated significant overall survival and radiographic progression-free survival benefits compared to ADT and docetaxel alone for patients with high volume disease.   Again, we add some practical information. Overall survival data for patients with low volume de novo metastatic noncastrate prostate cancer from the PEACE-1 trial are still too immature to justify recommending abiraterone-based triplet therapy, in other words, abiraterone and prednisone plus ADT and docetaxel, for patients with low volume de novo metastatic noncastrate disease.   A second new recommendation, as opposed to a revised recommendation with respect to triplet therapy, is: for patients with de novo metastatic noncastrate prostate cancer who are being offered ADT plus docetaxel chemotherapy, triplet therapy, darolutamide plus ADT and docetaxel should be offered per the ARASENS trial. Compared to placebo plus ADT and docetaxel, darolutamide plus ADT and docetaxel demonstrated significant overall survival benefits, in addition to significantly longer times to castration-resistant prostate cancer, pain progression, first skeletal event, and initiation of subsequent systemic antineoplastic therapy.   The practical information offered here is that discussion with patients should include the cost of darolutamide treatment compared with other options, such as abiraterone. There was no change to the 2021 recommendation for enzalutamide other than to report long term results from the ENZAMET and ARCHES trials that was not available in 2021. We added similar practical information here with respect to discussing costs of enzalutamide treatment. Discussion with patients should include the cost of enzalutamide treatment compared with other options, such as abiraterone.  Brittany Harvey: Excellent. I appreciate you reviewing those new and updated recommendations from the expert panel along with that practical information.   So then, Dr. Virgo, what should clinicians know as they implement these updated recommendations? And also, in your view, how will these guideline recommendations affect patients with noncastrate metastatic prostate cancer?   Dr. Katherine Virgo: That's a good question. Clearly, cost is a factor for patients, and we felt it was important to emphasize this in the guideline update. In the data supplement to the guideline update, we included a table listing all the agents discussed in the update, as well as the associated pivotal trials, main outcomes, the control group, the cost per cycle of treatment, and the cost for the full treatment course. This should be particularly helpful to clinicians as they discuss treatment options with patients. We also thought it would be helpful to have a visual guide to treatment options that reflects the clinician's decision-making process more directly. So figure one is the result of a group effort to achieve that aim.  Brittany Harvey: Excellent. And there have been a lot of changes in this field that prompted this update, but what are the outstanding questions regarding triplet therapy in the treatment of patients with metastatic noncastrate prostate cancer?   Dr. Katherine Virgo: Well, the burning question is whether docetaxel is really still necessary in the treatment of patients with metastatic noncastrate prostate cancer. No phase III clinical trials have yet compared, for example, androgen deprivation therapy plus darolutamide or androgen deprivation therapy plus abiraterone versus androgen deprivation therapy plus docetaxel. Also improved overall survival for patients undergoing triplet therapy is largely confined at present to those with high volume disease. So for patients with low-volume disease, clinical trials as yet show no significant benefit of triplet therapy.  Brittany Harvey: Great. Well, then I guess we'll look forward to future trials to determine if that's still appropriate and look for future updates of this guideline.   So I want to thank you so much for your time developing and updating this guideline. And thank you for joining me today, Dr. Virgo.  Dr. Katherine Virgo: Thank you. I appreciate it.   Brittany Harvey:  And thank you to all of our listeners for tuning in to the ASCO Guidelines Podcast. To read the full guideline, go to www.asco.org/genitourinary-cancer-guidelines. You can also find many of our guidelines and interactive resources in the newly redesigned ASCO Guidelines app, available for free in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe, so you never miss an episode.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.     

Amidst the battle of the mental health crisis, major depressive disorder stands out as an all-too-common reality for many children and adolescents, but the forces of science and medicine can stand against this foe. Dr. Christopher Drescher, a clinical child psychologist, joins pediatric resident Dr. Daniel Allen and medical student Vuk Lacmanovic to remove the cape from this increasingly common condition and discuss its symptoms, diagnosis, and treatment. Specifically, they will: Define major depressive disorder (MDD) and recognize the common symptoms in both children and adolescents. Formulate a differential diagnosis for patients presenting with depressive symptoms. Recognize validated screening tools for depression in both children and adolescents. Review cognitive behavioral therapy and pharmacotherapy as treatment options. Review appropriate referral to a mental health specialist. Free CME Credit (requires sign-in): https://mcg.cloud-cme.com/course/courseoverview?P=0&EID=12493  References: Bhatia SK, Bhatia SC. Childhood and adolescent depression. Am Fam Physician. 2007 Jan 1;75(1):73-80. PMID: 17225707. Brent DA, Maalouf F. Depressive Disorders (in Childhood and Adolescence). In: Ebert MH, Leckman JF, Petrakis IL. eds. Current Diagnosis & Treatment: Psychiatry, 3e. McGraw-Hill; Accessed November 17, 2020. https://accessmedicine.mhmedical.com/content.aspx?bookid=2509§ionid=200807606 Clark MS, Jansen KL, Cloy JA. Treatment of childhood and adolescent depression. Am Fam Physician. 2012 Sep 1;86(5):442-8. PMID: 22963063. Fendrich M, Weissman MM, Warner V. Screening for depressive disorder in children and adolescents: validating the Center for Epidemiologic Studies Depression Scale for Children. Am J Epidemiol. 1990 Mar;131(3):538-51. doi: 10.1093/oxfordjournals.aje.a115529. PMID: 2301363. (PDF of CES-DC here) Forman-Hoffman V, McClure E, McKeeman J, Wood CT, Middleton JC, Skinner AC, Perrin EM, Viswanathan M. Screening for Major Depressive Disorder in Children and Adolescents: A Systematic Review for the U.S. Preventive Services Task Force. Ann Intern Med. 2016 Mar 1;164(5):342-9. doi: 10.7326/M15-2259. Epub 2016 Feb 9. PMID: 26857836. Hathaway EE, Walkup JT, Strawn JR. Antidepressant Treatment Duration in Pediatric Depressive and Anxiety Disorders: How Long is Long Enough? Curr Probl Pediatr Adolesc Health Care. 2018 Feb;48(2):31-39. doi: 10.1016/j.cppeds.2017.12.002. Epub 2018 Jan 12. PMID: 29337001; PMCID: PMC5828899. March JS, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J. The Treatment for Adolescents With Depression Study (TADS): long-term effectiveness and safety outcomes. Arch Gen Psychiatry. 2007 Oct;64(10):1132-43. doi: 10.1001/archpsyc.64.10.1132. Erratum in: Arch Gen Psychiatry. 2008 Jan;65(1):101. PMID: 17909125. Meister R, Abbas M, Antel J, Peters T, Pan Y, Bingel U, Nestoriuc Y, Hebebrand J. Placebo response rates and potential modifiers in double-blind randomized controlled trials of second and newer generation antidepressants for major depressive disorder in children and adolescents: a systematic review and meta-regression analysis. Eur Child Adolesc Psychiatry. 2020 Mar;29(3):253-273. doi: 10.1007/s00787-018-1244-7. Epub 2018 Dec 8. PMID: 30535589; PMCID: PMC7056684. Rachel A. Zuckerbrot, Amy Cheung, Peter S. Jensen, Ruth E.K. Stein, Danielle Laraque and GLAD-PC STEERING GROUP. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part I. Practice Preparation, Identification, Assessment, and Initial Management. Pediatrics March 2018, 141 (3) e20174081; DOI: https://doi.org/10.1542/peds.2017-4081 Scott K, Lewis CC, Marti CN. Trajectories of Symptom Change in the Treatment for Adolescents With Depression Study. J Am Acad Child Adolesc Psychiatry. 2019 Mar;58(3):319-328. doi: 10.1016/j.jaac.2018.07.908. Epub 2019 Jan 8. PMID: 30768414; PMCID: PMC6557284. Sharma T, Guski LS, Freund N, Gøtzsche PC. Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. BMJ. 2016 Jan 27;352:i65. doi: 10.1136/bmj.i65. PMID: 26819231; PMCID: PMC4729837. Siu AL; US Preventive Services Task Force. Screening for Depression in Children and Adolescents: US Preventive Services Task Force Recommendation Statement. Pediatrics. 2016 Mar;137(3):e20154467. doi: 10.1542/peds.2015-4467. Epub 2016 Feb 8. PMID: 26908686. Weersing VR, Brent DA, Rozenman MS, Gonzalez A, Jeffreys M, Dickerson JF, Lynch FL, Porta G, Iyengar S. Brief Behavioral Therapy for Pediatric Anxiety and Depression in Primary Care: A Randomized Clinical Trial. JAMA Psychiatry. 2017 Jun 1;74(6):571-578. doi: 10.1001/jamapsychiatry.2017.0429. PMID: 28423145; PMCID: PMC5539834. Weersing VR, Shamseddeen W, Garber J, Hollon SD, Clarke GN, Beardslee WR, Gladstone TR, Lynch FL, Porta G, Iyengar S, Brent DA. Prevention of Depression in At-Risk Adolescents: Predictors and Moderators of Acute Effects. J Am Acad Child Adolesc Psychiatry. 2016 Mar;55(3):219-26. doi: 10.1016/j.jaac.2015.12.015. Epub 2016 Jan 18. PMID: 26903255; PMCID: PMC4783159. Xu Y, Bai SJ, Lan XH, Qin B, Huang T, Xie P. Randomized controlled trials of serotonin-norepinephrine reuptake inhibitor in treating major depressive disorder in children and adolescents: a meta-analysis of efficacy and acceptability. Braz J Med Biol Res. 2016 May 24;49(6):e4806. doi: 10.1590/1414-431X20164806. PMID: 27240293; PMCID: PMC4897997. Zhou X, Cipriani A, Zhang Y, Cuijpers P, Hetrick SE, Weisz JR, Pu J, Giovane CD, Furukawa TA, Barth J, Coghill D, Leucht S, Yang L, Ravindran AV, Xie P. Comparative efficacy and acceptability of antidepressants, psychological interventions, and their combination for depressive disorder in children and adolescents: protocol for a network meta-analysis. BMJ Open. 2017 Aug 11;7(8):e016608. doi: 10.1136/bmjopen-2017-016608. PMID: 28801423; PMCID: PMC5629731. Zhou X, Teng T, Zhang Y, Del Giovane C, Furukawa TA, Weisz JR, Li X, Cuijpers P, Coghill D, Xiang Y, Hetrick SE, Leucht S, Qin M, Barth J, Ravindran AV, Yang L, Curry J, Fan L, Silva SG, Cipriani A, Xie P. Comparative efficacy and acceptability of antidepressants, psychotherapies, and their combination for acute treatment of children and adolescents with depressive disorder: a systematic review and network meta-analysis. Lancet Psychiatry. 2020 Jul;7(7):581-601. doi: 10.1016/S2215-0366(20)30137-1. PMID: 32563306; PMCID: PMC7303954.

Listner questions and my (rambling) answers. REFERENCES Baize, Kohman, Stoffel, Weigartz. (2021). Albuterol versus terbutaline in emergency department management of asthma or COPD exacerbation. Critical Care Medicine 49(1 suppl 1): 410. Busti. (2015). Nitroglycerin Use in the Initial Management of Ischemic Pain from Acute Myocardial Infarction (NSTEMI, STEMI). Available: https://www.ebmconsult.com/articles/nitroglycerin-use-in-initial-management-ischemic-pain-acute-myocardial-infarction-nstemi-stemi Mike Sarraille, George Randle, Josh Cotton. The Talent War: How Special Operations and Great Organizations Win on Talent. Salim Rezaie, "The Death of MONA in ACS: Part III – Nitroglycerin", REBEL EM blog, November 5, 2017. Available at: https://rebelem.com/death-mona-acs-part-iii-nitroglycerin/.

As Dr. Debbie A. Rinde-Hoffman discusses contemporary recognition and initial management of cardiogenic shock in 2022, listeners will be able to identify when to consider shock as the diagnosis, recognize how to diagnose the etiology, and discover the management options available. AccreditationsPHYSICIANSACCMEUSF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. USF Health designates this live activity for a maximum of (PLEASE ITALICIZE THEN REMOVE THIS NOTE) 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Florida Board of MedicineUSF Health is an approved provider of continuing education for physicians through the Florida Board of Medicine. This activity has been reviewed and approved for up to 0.25 continuing education credits. Relevant Financial Relationships All individuals in a position to influence content for this activity have disclosed to USF Health any financial relationship they have with an ineligible organization. There are no relevant financial relationship to disclose or mitigate.Target Audience: cardiologists, internal medicine, and/or APPs with a cardiology interestRelease Date: June 14th, 2022Expiration Date: June 14th, 2023Claim CME/CEU Credit for this episode here: https://cmetracker.net/USF/Publisher?page=pubOpen#/getCertificate/352996 Visit cme.tgh.org for other CME opportunities, including live webinars, on-demand videos and local events offered to you by Tampa General Hospital.

This podcast is a two part interview with Dr Caroline Sampson, ECMO and intensive care consultant, on the topic of the clinical management of ARDS . This first part discusses some aspects of who benefits from escalation to intensive care, as well as strategies to avoid intubation, and how the decision to intubate is made. 

In this podcast, Dr Agnes Watson and Dr Claire McCann talk us through the epidemiology, pathophysiology and initial management of Major Burns. This is the first article of a 2 part Burns series in the BJA Education and provides the essential information for initial management.

Paper for discussion: Analgesia in the Initial Management of Acute Pancreatitis: A Systematic Review and Meta-Analysis of Randomised Controlled Trials - WJS Jan 2022 Teaching topic: Evidence Based Medicine for Surgeons and Trainees - part 4 Our tune is"Inspiring Optimistic Upbeat Energetic Guitar Rhythm" by Free Music | https://soundcloud.com/fm_freemusic Music promoted by https://www.free-stock-music.com Creative Commons Attribution 3.0 Unported License https://creativecommons.org/licenses/by/3.0/deed.en_US

In this first of two podcasts, 2 experts discuss risk factors and current recommendations for the diagnostic workup of ITP, and share strategies for initial management of newly diagnosed disease. Topics including corticosteroid overuse, approaches to improve remission rates, and contemporary concerns with COVID vaccination will be covered.. This activity is available for CE/CME credit. Claim your credit at pce.is/ITP.Contributors:Hanny Al-Samkari, MDAssistant ProfessorHarvard Medical SchoolAttending Hematologist and Clinical InvestigatorDivision of Hematology OncologyMassachusetts General HospitalBoston, MassachusettsChristopher Nelson, ACNP-BC, MBANurse PractitionerHematology and OncologyAvera Cancer InstituteAvera St Luke's HospitalAberdeen, South DakotaDr Al-Samkari: consultant/advisor/speaker: Argenx, Forma, Moderna, Novartis, Rigel; consultant/research funding (paid to institution): Agios, Amgen, Dova/Sobi.Mr Nelson: consultant/advisor/speaker: Amgen, AbbVie, AstraZeneca, Bristol-Myers Squibb/Celgene, Beigene, Incyte, Karyopharm, Rigel, Sanofi.

A discussion on the initial management of meniscus tears. Learn what to do to get rehab started early and discover whether the meniscus can heal by itself on @cutandrunpodcast Season 3 Episode 3What is the initial management directly after the injury?Do you need crutches?Do you need a brace?Can a meniscus heal?Will surgery help it heal?Do all meniscus tears require surgery?Thanks for listening If you have any questions then send us an email at cutandrunpodcast@gmail.com to let us know if you have any topics you would like us to cover. See you next time.

Today, we discuss the management of stroke, stroke scales, workup, imaging modalities, and therapeutic approach. Dr. Samir Ruxmohan is a 4th year Neurology Resident at Larkin Community Hospital and an incoming Fellow in Neurocritical Care at the University of Texas Southwestern.

In this month's podcast Riaz Aziz talks to Dr James Shilston and Mr Anthony Simons about their September 2021 article on neck trauma. We get an anaesthetist and ENT surgeons' perspective on management of such injuries and useful practical advice on how to manage such injuries outside specialised trauma centres.

What is the incidence of post-COVID myocarditis and when is it safe to return to play? Bob Harrington and Manesh Patel discuss our evolving understanding of how SARS-CoV-2 effects the hearts of athletes and weekend warriors. To read a transcript or to comment https://www.medscape.com/author/bob-harrington Early Studies Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19) https://doi.org/10.1001/jamacardio.2020.3557 Cardiovascular Magnetic Resonance Findings in Competitive Athletes Recovering From COVID-19 Infection https://doi.org/10.1001/jamacardio.2020.4916 Pooled autopsy https://www.medscape.com/viewarticle/944496 Pathological Evidence for SARS-CoV-2 as a Cause of Myocarditis: JACC Review Topic of the Week https://doi.org/10.1016/j.jacc.2020.11.031 Lake Louise Criteria https://pubmed.ncbi.nlm.nih.gov/30545455/ Recognition and Initial Management of Fulminant Myocarditis A Scientific Statement From the American Heart Association https://doi.org/10.1161/CIR.0000000000000745 Long-Haul Post–COVID-19 Symptoms Presenting as a Variant of Postural Orthostatic Tachycardia Syndrome: The Swedish Experience https://doi.org/10.1016/j.jaccas.2021.01.009 You may also like: Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine https://www.medscape.com/features/public/machine Hear John Mandrola, MD's summary and perspective on the top cardiology news each week, on This Week in Cardiology https://www.medscape.com/twic Questions or feedback, please contact news@medscape.net

An interview with Dr. Katherine S. Virgo from Emory University in Atlanta, GA on “Initial Management of Non-Castrate Advanced, Recurrent or Metastatic Prostate Cancer: ASCO Guideline Update.” This guideline updates recommendations for initial hormonal management of non-castrate advanced, recurrent, or metastatic prostate cancer. Read the full guideline at www.asco.org/genitourinary-cancer-guidelines. TRANSCRIPT PRESENTER: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care, and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. BRITTANY HARVEY: Hello, and welcome to the ASCO Guidelines podcast series, brought to you by the ASCO Podcast Network, a collection of nine programs covering a range of educational and scientific content and offering enriching insight into the world of cancer care. You can find all the shows, including this one, at podcast.asco.org. My name is Brittany Harvey, and today I'm interviewing Dr. Katherine Virgo from Emory University, lead author and co-chair on initial management of non-castrate advanced, recurrent, or metastatic prostate cancer, ASCO guideline update. Thank you for being here, Dr. Virgo. DR. KATHERINE VIRGO: Thank you, Brittany. BRITTANY HARVEY: First, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO conflict of interest policy is followed for each guideline. The full conflict of interest information for this guideline panel is available online with the publication of the guideline in the Journal of Clinical Oncology. Dr. Virgo, do you have any relevant disclosures that are directly related to this guideline topic? DR. KATHERINE VIRGO: No, I do not. BRITTANY HARVEY: OK, thanks. Then let's delve into some of the guideline content. What prompted this update of the initial management of non-castrate advanced, recurrent, or metastatic prostate cancer guideline, and what is the scope of the update? DR. KATHERINE VIRGO: Well, the update of the 2007 version of the guideline was largely prompted by the many Phase III randomized clinical trials that had been completed or were nearly complete in the non-castrate space. It was believed that the results of these trials might permit revisiting previous recommendations regarding intermittent versus continuous androgen deprivation therapy and early or immediate versus deferred androgen deprivation therapy. As you might imagine, it took quite some time to gather and review 13 years of literature for each of the study questions from the original 2007 guideline. So in the interim, a sufficient number of randomized clinical trials reached completion to also inform recommendations regarding the use of newer therapies in combination with androgen deprivation therapy as initial therapy for men with metastatic disease, such as docetaxel, abiraterone, enzalutamide, and apalutamide, and thereby also update another existing ASCO guideline authored by Morris et al in 2018, which previously only provided guidance on the use of docetaxel and abiraterone for men with metastatic disease. BRITTANY HARVEY: Great, yeah, definitely a large volume of literature to review there. So then you talked about the recommendations. So I'd like to go through some of those. For men with metastatic non-castrate prostate cancer, what are the recommended standard initial treatment options? KATHERINE VIRGO: So docetaxel, abiraterone, enzalutamide, and apalutamide, each when administered with androgen deprivation therapy, represent four separate standards of care for non-castrate metastatic prostate cancer. The use of any of these agents in any particular combination or in any particular series cannot yet be recommended. That said, we were able to make a recommendation for each agent individually. So I'll go through those recommendations now, first for docetaxel. So for men with metastatic non-castrate prostate cancer with high-volume disease who are candidates for treatment with chemotherapy, the addition of docetaxel to androgen deprivation therapy should be offered. Here, high-volume disease is defined per the charted trial as four or more bone metastases, one or more of which is outside of the spine or pelvis, and/or the presence of any visceral disease. Second, for abiraterone, for men with high-risk de novo metastatic non-castrate prostate cancer, the addition of abiraterone to androgen deprivation therapy should be offered per the latitude trial. For men who are considered low-risk, androgen deprivation therapy plus abiraterone may be offered for the STAMPEDE trial. Third, for enzalutamide, androgen deprivation therapy plus enzalutamide should be offered to men with metastatic non-castrate prostate cancer, including those with de novo metastatic disease and those who have received prior therapies, such as radical prostatectomy or radiation therapy for localized disease. Enzalutamide plus ADT has demonstrated short-term survival benefits, such as PSA progression-free, clinical progression free, and overall survival when compared to androgen deprivation therapy alone for men with metastatic non-castrate prostate cancer per the ENZAMET trial. And finally, fourth, androgen deprivation therapy plus apalutamide should be offered to men with metastatic non-castrate prostate cancer, including those with de novo metastatic disease or those who have received prior therapy, such as radical prostatectomy or radiation therapy for localized disease, per the TITAN trial. Thus in summary, to your initial question, all of the recommendations were phrased as "should be offered" except in the case of androgen deprivation therapy plus abiraterone for men with low-risk de novo metastatic non-castrate prostate cancer, for which the recommendation was phrased as "may be offered," as the evidence was not as strong as for the other recommendations. BRITTANY HARVEY: Great, thank you for reviewing those standard initial treatment options for men with metastatic non-castrate prostate cancer. So then what does the guideline say regarding combination therapy for men with non-castrate locally advanced non metastatic prostate cancer? DR. KATHERINE VIRGO: So here, androgen deprivation therapy plus abiraterone and prednisolone should be considered for men with non-castrate locally advanced non-metastatic prostate cancer, rather than castration monotherapy, due to the failure-free survival benefit for the STAMPEDE trial. We were unable to make a recommendation for men with high-risk non-metastatic prostate cancer progressing after radical prostatectomy or radiotherapy or both, as it's currently unclear whether enzalutamide in the 160-milligram dose plus leuprolide improved metastasis-free survival compared to enzalutamide monotherapy or placebo. The recruitment is complete for the ongoing Phase III EMBARK trial, which is designed to answer this question. The results are not available yet. BRITTANY HARVEY: Great. Then how does the guideline address early or immediate androgen deprivation therapy versus deferred therapy for men with non-castrate locally advanced non-metastatic prostate cancer? DR. KATHERINE VIRGO: So here, early or immediate androgen deprivation therapy may be offered to men who initially present with non-castrate locally advanced non-metastatic disease who have not undergone previous local treatment, and are either unwilling or unable to undergo radiotherapy, based on evidence in one meta-analysis of a modest but statistically significant benefit in terms of both overall survival and cancer-specific survival among the larger population of men with locally advanced non-metastatic disease. Unfortunately, we were unable to make a recommendation for men with PSA relapse after local treatment. Though existing studies suggest a potential overall survival benefit, additional research is needed, as such studies were underpowered. BRITTANY HARVEY: And then finally, for men with biochemically recurrent non-metastatic disease, what are the recommendations for intermittent androgen deprivation therapy versus continuous androgen deprivation therapy? DR. KATHERINE VIRGO: So intermittent therapy may be offered to men with high-risk, biochemically recurrent non-metastatic prostate cancer after radical prostatectomy and/or radiotherapy, based on evidence and meta-analyses of the non-inferiority of intermittent androgen deprivation therapy when compared to continuous androgen deprivation therapy, with respect to overall survival. This is further supported by evidence from four meta-analyses testing superiority. And here, high-risk biochemical recurrence after radical prostatectomy is defined as a PSA doubling time less than one year or a pathologic Gleason score of 8 to 10. High-risk biochemical recurrence after radiation therapy has a different definition, here defined as an interval to biochemical recurrence of less than 18 months or a clinical Gleason score of 8 to 10. BRITTANY HARVEY: Thank you for reviewing all those recommendations and the evidence supporting them. It's very interesting to hear where you were able to make recommendations and where you weren't. So in your view, what is the importance of this guideline, and how will it change practice? DR. KATHERINE VIRGO: As mentioned earlier, the previous version of the guideline was 13 years old. And practice, as you might imagine, has changed considerably in the interim. Though consensus documents have been issued by other organizations since that time, it was important, given ASCO's global audience, to provide up-to-date, evidence-based guidance for the organization's worldwide membership. Practice patterns of most clinicians based at large university medical centers likely approximate the guidance provided in the ASCO guideline update, at least with respect to the treatment of men with de novo metastatic high-risk or high-volume disease. Some may be surprised by the current lack of evidence for the use of docetaxel among patients with de novo metastatic low-volume disease. The new guidelines should be particularly useful for community-based clinicians, who may not be as actively involved in clinical trial enrollment. BRITTANY HARVEY: Definitely. And then finally, how will these guideline recommendations impact patients with prostate cancer? DR. KATHERINE VIRGO: So patients will be impacted in three ways. First, the guidelines should be helpful to patients in understanding the various treatment options available to them, depending on the extent of their disease and any previous treatment they may have already received. The guidelines also highlight treatment options that should not be offered to patients who have certain characteristics and hopefully assist patients with adjusting their treatment expectations. Second, the cost table in the guidelines should also be helpful to patients, as it provides some idea of how costs vary by the type of treatment received, while also indicating when a less costly generic equivalent is available. And finally, third, the guidelines suggest that patients be counseled about the potential side effects associated with androgen deprivation therapy, such as depression, dementia, stroke, myocardial infarction, deep venous thrombosis, hot flush, fatigue, and nausea. Side effects vary by type of androgen deprivation therapy, as well as by age and patient comorbidities. Knowing up-front that such side effects are possible can assist patients in having more informed conversations with their physician when treatment discussions are underway. BRITTANY HARVEY: Great. Then it sounds like these guidelines have a real impact for both community oncologists and for patients. So I want to thank you for your leadership on the development of these evidence-based guidelines, and thank you for taking the time to speak with me today, Dr. Virgo. DR. CATHERINE VIRGO: Thank you, Brittany. BRITTANY HARVEY: And thank you to all of our listeners for tuning in to the ASCO Guidelines podcast series. To read the full guideline, go to www.asco.org/genitourinary-cancer-guidelines.  You can also find many of our guidelines and interactive resources in the free ASCO guidelines app, available in iTunes or the Google Play store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode.

Acute pancreatitis can be a devastating disease. Complications of pancreatitis can be minimized by appropriate early, initial management. Joe Hines, MD, and Raman Muthusamy, MD, from UCLA discuss the recent American Gastroenterological Association guideline on managing acute pancreatitis. Related Article(s): Initial Management of Acute Pancreatitis

HeartBEATS from Lifelong LearningTM, Science Series welcomes listeners to dive deeper into current science in podcasts hosted by AHA FIT members, Dr. Elizabeth Dineen and Dr. Jeff Hsu. Listen to a discussion on AHA’s scientific statement entitled, The Recognition and Initial Management of Fulminant Myocarditis by Dr. Leslie Cooper, the Vice Chair of the committee that published the statement. Dr. Cooper is Chair of the Department of Cardiovascular Medicine at the Mayo Clinic in Florida. This statement was endorsed by the Heart Failure Society of America, or HFSA, as well as the Myocarditis Foundation.

HeartBEATS from Lifelong LearningTM, Science Series welcomes listeners to dive deeper into current science in podcasts hosted by AHA FIT members, Dr. Elizabeth Dineen and Dr. Jeff Hsu. Listen to a discussion on AHA's scientific statement entitled, The Recognition and Initial Management of Fulminant Myocarditis by Dr. Leslie Cooper, the Vice Chair of the committee that published the statement. Dr. Cooper is Chair of the Department of Cardiovascular Medicine at the Mayo Clinic in Florida. This statement was endorsed by the Heart Failure Society of America, or HFSA, as well as the Myocarditis Foundation.

Tine Sylvest Meyhoff, MD, and Jonathan A. Silversides, MBBCh, PhD, join CHEST Podcast Moderator, Dominique J. Pepper, MD, to discuss patient-important benefits and harms of lower vs higher fluid volumes in adult patients with sepsis. DOI: https://doi.org/10.1016/j.chest.2019.11.050 DOI: https://doi.org/10.1016/j.chest.2020.01.015

Time is tissue. Early recognition of shock with immediate institution of lifesaving therapies are critical to successful patient outcomes. Establishment of functional IV access together with augmentation of cardiac output through increased preload and appropriate use of vasoactive agents are key aspects in the initial management of sick patients.

Today on MedNet21, we're going to discuss Epidemiology and Initial Management of COVID-19.

Today on MedNet21, we're going to discuss Epidemiology and Initial Management of COVID-19.

This podcast reviews 3 articles. Shared Blood: Expeditionary Resuscitative Surgical Team (ERST-5) Use of Local Whole Blood to Improve Resuscitation of Host Nation Partner Forces by Melanie Bowman, et. al., The Good, the Bad, and the Future of Drones in Tactical/Operational Medicine by Keegan Bradley, and Guest host Ricky Ditzel, Research and Development lead @ SOM-C, will review Getting "SMART" on Shock Treatment: An Evidence-Based Mnemonic Acronym for the Initial Management of Hemorrhage by Patrick Thompson and Anthony Hudson. Visit our Social Media @jsomonline. https://jsom.us/Podcast.

This educational series is supported by independent educational grants from: AbbVie, Astellas and Pfizer, Inc., AstraZeneca, Bayer HealthCare Pharmaceuticals Inc., Genomic Health, Merck, Sanofi Genzyme Episode 1: Genetic Testing in Advanced Prostate Cancer and the Identification of High Risk Disease and Initial Management of Biochemical Recurrence CME Available: https://auau.auanet.org/node/25403 The AUA is launching an educational initiative to focus on resident and fellow training in the area of Advanced and Castration-Resistant Prostate Cancer. Based on the documented need for additional education in this area, the AUA in collaboration with Society of Urologic Oncology (SUO) has developed multiple educational interventions to improve the ability to care for patients with CRPC. These educational activities may also be of interest to advanced practice providers and urologists. To extend the educational reach, the AUA will capture the live presentations and develop three podcasts with a faculty interview segment.

Acute respiratory distress syndrome (ARDS) is a severe form of respiratory failure that affects approximately 200,000 patients each year in the United States, resulting in nearly 75,000 deaths annually. In this episode of Critical Matters, our guest Dr. R. Phillip Dellinger discusses the current management of patients with ARDS. Dr. Dellinger is a recognized thought leader in the field, a prolific author, an accomplished researcher, and the recipient of multiple awards for his contributions to critical care. ADDITIONAL RESOURCES: The PROSEVA clinical trial showed that in patients with severe ARDS prone position ventilation improved mortality: https://bit.ly/2Dp3LdS The ACURASYS clinical study showed that in patients with severe ARDS 48 hours of neuromuscular blockade was associated with improved mortality: https://bit.ly/2FqI7Zn The EOLIA study was stooped early for futility. However, many think that it still has important findings regarding the use of ECMO in severe ARDS: https://bit.ly/2QI1Cxu BOOKS MENTIONED IN THIS EPISODE: Evidence-Based Critical Care: A Case Study Approach: https://amzn.to/2PYeD8V

Are you providing consistent burns care? Listen in as Toby St Clair, a MICA Flight Paramedic & Yvonne Singer the Victorian Burns Program Coordinator talk us through the initial management of burns. Toby discusses some of the challenges & priorities of pre-hospital burns management and provides a practical approach to their care. Yvonne provides us insight into the continuum of care on arrival to the Victorian Adult Burns service & management advice supported by burns literature. Current at date of publication; 11/06/2019.

Chronic pelvic pain is common and affects around one in six adult women in the UK. Dr Louise Newson, a GP and Menopause expert in the West Midlands and author of the EKU module on the Initial Management of Chronic Pelvic Pain speaks to Dr Thomas Round, EKU Development Fellow about this topic.

The Changing Landscape of Advanced Prostate Cancer Management: What You Need to Know is the first podcast in a 4-part series. Topics will include "Initial Management and Imaging of Advanced Prostate Cancer" and "Chemo-hormonal Therapy for Metastatic Hormone-Sensitive Prostate Cancer ". CME Available: https://auau.auanet.org/node/19906

Discussion of the diabetes care process model with Dr. Elizabeth Bernstein of Asheville Endocrinology

Hans J. Lee, MD, and Malcolm DeCamp, MD, join CHEST podcast editor D. Kyle Hogarth, MD, FCCP, to discuss the merits, pro and con, on the benefits of a small- vs. large bore catheter.

Thank you for listening to this podcast, where Frontline Gastroenterology Trainee Editor Dr Philip Smith talks to Professor Mark Pritchard, Professor and Head of the Department of Gastroenterology and Honorary Consultant Gastroenterologist at the University of Liverpool, UK. The podcast is an accompaniment to the Frontline Gastroenterology Twitter Debate (#FGDebate) held on Tuesday 10th February 2015, 8-9pm GMT, entitled, 'Frontline Gastrointestinal NETs: The approach to diagnosis and initial management'. Prior to the debate Professor Pritchard said: 'Neuroendocrine tumours (NETs) are relatively rare, but because they are often associated with a good prognosis, they have a high prevalence. They are said to be more prevalent than stomach and exocrine pancreatic cancers combined. There is often a delay in initial diagnosis as NETs may cause similar symptoms to other more common conditions such as IBS. As many patients present with metastatic disease at the time of diagnosis, management usually requires the involvement of a multidisciplinary team of clinicians. A gastroenterologist is a crucial member of this team, as many NETs occur in the GI tract and pancreas where they are amenable to endoscopic detection, evaluation and removal. In the #FGDebate we hope to cover the endoscopic evaluation of NETs, particularly how to determine the type of a gastric NET and whether it requires treatment. We will also discuss other tests, particularly how to interpret chromogranin A blood test results and the role of the new highly sensitive and specific PET scans. There have also been several recent advances in NET management, such as clinical trial evidence to support the use of long acting somatostatin analogues to delay disease progression as well as treat the symptoms of carcinoid syndrome, the more widespread use of targeted radionuclide therapies for metastatic NETs and the development of new drugs such as gastrin/CCK-2 receptor antagonists to treat specific tumour types. Finally we hope to consider how easy it is for patients to access specialist NET teams and therefore the various investigations and treatments that may be needed for optimal management’ The purpose of the podcast is to 'fill any gaps' the #FGDebate may have left. Professor Pritchard has also provided the slides he used in #FGDebate to help those interested understand the issues associated with Gastrointestinal NETs. We hope you enjoy this and that it is informative. View the slides: http://goo.gl/x159bU Don't miss the next #FGDebate with Professor Brian Saunders, Consultant Gastroenterologist at St Mark’s Hospital, London and Adjunct Professor of Endoscopy at Imperial College London on Tuesday 3rd March 2015, at 8-9pm GMT and will discuss, 'Frontline Endoscopy: Polypectomy – tips, tricks and which to remove endoscopically.’

In this first of the new video lectures we look at the initial management of trauma. It covers all the basics of ATLS and additionally looks at the current guidelines being used in the UK major trauma centres.

A Pecha Kucha introducing the topic of aneurysmal subarachnoid haemorrhage. This includes some epidemiology, the initial management and some treatment options. This is the first of five Pecha Kuchas on this topic.

This podcast focuses on the diagnosis and management of choroidal neovascularization.